About BioCryst
BioCryst is a publicly listed company based in Durham (United States) founded in 1986. Developer of small molecule drugs for orphan autoimmune diseases and antivirals. The company has 580 employees. BioCryst has completed 1 acquisition, including Astria Therapeutics. Its chief executive, as recorded, is Jon Stonehouse. Its website biocryst.com draws about 16 thousand monthly visits. BioCryst offers products and services including Oral Small-Molecule Therapeutics and Protein Therapeutics. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified. Its legal entity is BioCryst Pharmaceuticals, Inc. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
BioCryst was founded in 1986 and is based in Durham, United States, within the biotechnology sector. Small molecule therapeutics are developed for orphan and autoimmune conditions, alongside antiviral agents. Operations focus on pipeline candidates such as BCX7353, targeted at hereditary angioedema, and BCX4430 (Galidesivir), a broad-spectrum antiviral for hemorrhagic fevers including SARS-CoV-2. RAPIVAB is also offered for influenza treatment.
- Headquarters Durham, United States
- Employees 580
- Stage Public
- SectorsHealthcare
- Website biocryst.com
- Social LinkedIn X Facebook Instagram
- Legal Name Biocryst Pharmaceuticals, Inc.
- Annual Revenue$874.84 M (USD)94.1as on Dec 31, 2025
- Net Profit$263.86 M (USD)as on Dec 31, 2025
- EBITDA$342.38 M (USD)as on Dec 31, 2025
- Latest Funding Round$350M (USD), Post-IPO
Nov 2021
- InvestorsKleiner Perkins
& 8 more
- Employee Count580
- Investments & Acquisitions
Products & Services of BioCryst
BioCryst offers a comprehensive portfolio of products and services, including Oral Small-Molecule Therapeutics and Protein Therapeutics.
Treatments for rare diseases like hereditary angioedema.
Innovative proteins targeting rare disease conditions.
Funding Insights of BioCryst
- Total Rounds 11
- Last Round Post-IPO — $350M
- First Round $65.3M
(Aug 2007)
- Investors Count 9
Latest 10 of 11 funding rounds of BioCryst with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | $350M | Post-IPO | – | – | |
| Dec 2020 | $325M | Post-IPO | – | – | |
| Feb 2019 | $100M | Debt – Conventional | – | – | |
| Sep 2018 | $3.5M | Grant | – | – | |
| Jul 2016 | $5.5M | Grant | – | – | |
| Sep 2014 | $4M | Grant | – | – | |
| Aug 2014 | $2.4M | Grant | – | – | |
| Aug 2014 | $4.1M | Grant | – | – | |
| Dec 2013 | $2.5M | Grant | – | – | |
| Sep 2013 | $5M | Grant | – | – |
9 investors in total: 9 institutional.
Investors in BioCryst
BioCryst has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Kleiner Perkins, Royalty Pharma and TPG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in marketed and late-stage biopharmaceutical companies. | 1996 | royaltypharma.com | New York, United States | |
Global private equity investments are managed by the firm. | athyrium.com | New York, United States | ||
Private debt funds are managed across multiple sectors. | 2008 | midcapfinancial.com | Bethesda, United States | |
Venture capital firm investing in early-stage tech startups | 1972 | kleinerperkins.com | Menlo Park, United States | |
Fund of funds focused on pre-seed and seed-stage companies | 1992 | tpg.com | Fort Worth, United States | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
OMERS is recognized as a leading institutional investor managing pension funds. | omerscapitalmarkets.com | Toronto, Canada | ||
| niaid.nih.gov | ||||
| stephens.com |
Investor details for BioCryst
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BioCryst
185 people are tracked at BioCryst (117 in leadership, 10 in board & advisors, 58 in team); the tracked headcount is 580.
| Name | Role | Group |
|---|---|---|
Jon Stonehouse | CEO | Leadership |
Anurag Mehta | Sr Vice President, Corporate Development | Leadership |
Raj Kapadia | Sr. Vice President Global Supply Chain | Leadership |
Patrick Wong | Executive Director, International Commercial Operations | Leadership |
Briana Saunders | Associate Director, Global Market Insights | Leadership |
Stephanie Angelini | Chief People Officer | Leadership |
Ryan Arnold | Chief Medical Officer | Leadership |
Becky Tso | Associate Director, HR Business Partner | Leadership |
Amara S. | Director, Operational Compliance | Leadership |
Kevin Greaney | Director Of European Legal | Leadership |
Helen Chuah | Vp, Commercial Strategy | Leadership |
Jason Stallings | Executive Director, Global Corporate Compliance Operations | Leadership |
Kenyon Hill | Executive Director, Global Payroll | Leadership |
Maxime Duboc | Commercial Director | Leadership |
Lauren Iacono | Vice President, Corporate Communications | Leadership |
Heather Iocca | Vp, Global Development & Product Team Leader | Leadership |
Rebekah Ziegenfuss | Regional Business Director | Leadership |
Ron Dullinger | Svp, General Manager-americas | Leadership |
Hendrik Brune | Head Of EMEA Mid-sized Markets & Benelux | Leadership |
Alexander Rendon | Associate Director, International Commercial Excellence | Leadership |
165 more people are available in the full profile.
Complete people profiles for BioCryst
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of BioCryst
BioCryst is a publicly listed company on the NASDAQ with ticker symbol BCRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date03 Mar 1994
- Listed onNASDAQ: BCRX
- Listed entityBioCryst Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS09058V1035
- Share price$8.07 (-3.47% on the day) · 2026-10-13
- Market capitalisation$2.06B
- EPS (diluted, trailing year)$-1.50
- Volume (last session)3,043,100
Financials of BioCryst
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $874.8M | $263.9M | $342.4M |
| 2024 | $450.7M | -$88.9M | -$1.3M |
| 2023 | $331.4M | -$226.5M | -$102.0M |
| 2022 | $270.8M | -$247.1M | -$147.0M |
| 2021 | $157.2M | -$184.1M | -$176.9M |
Detailed financial statements for BioCryst
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioCryst
BioCryst has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Astria Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutics for rare diseases, including hereditary angioedema inhibitors, are developed. | astriatx.com | Boston, United States | 2008 | Oct 2025 | $920M |
Complete acquisition details for BioCryst
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of BioCryst
5 dated milestones of BioCryst across 39 years, from founding to its latest funding, stage changes and deals.
- Founded BioCryst is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $65.3M.
- Funding Latest funding round, Post-IPO, of $350.0M.
- Acquisition Acquires Astria Therapeutics.
Competitors of BioCryst
BioCryst has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of BioCryst
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BioCryst
The website of BioCryst (biocryst.com) receives about 16.2K visits a month.
- Monthly visits16.2K
▲ 10.4% vs previous month
Websites whose visitors overlap most with BioCryst. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| scfbio-iitd.res.in | 100% | 16.2K | #1,738,694 | View details | |
| incyte.com | 96% | 82.2K | #247,619 | View details | |
| dionex.com | 96% | View details | |||
| bruker.com | 96% | 346K | #136,650 | View details | |
| alnylam.com | 96% | 77.8K | #414,009 | View details |
Top companies in Rare Diseases
3 companies that operate in the same segment as BioCryst (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biocryst
Complete news archive for BioCryst
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioCryst
BioCryst was founded in 1986 and raised its 1st funding round 21 years after it was founded.
BioCryst is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Jon Stonehouse is the CEO of BioCryst, as recorded in our data.
BioCryst has 580 employees.
Annual revenue of BioCryst is $874.84M as on Dec 31, 2025.
BioCryst was founded in 1986 and is based in Durham, United States, within the biotechnology sector. Small molecule therapeutics are developed for orphan and autoimmune conditions, alongside antiviral agents. Operations focus on pipeline candidates such as BCX7353, targeted at hereditary angioedema, and BCX4430 (Galidesivir), a broad-spectrum antiviral for hemorrhagic fevers including SARS-CoV-2. RAPIVAB is also offered for influenza treatment.
BioCryst's top competitors include Moderna, Spark Therapeutics and BridgeBio.
BioCryst offers Oral Small-Molecule Therapeutics and Protein Therapeutics.
Yes, BioCryst is publicly traded on NASDAQ under the ticker symbol BCRX.
BioCryst has made 1 acquisition, including Astria Therapeutics.
BioCryst has 9 investors. Key investors include Kleiner Perkins, Royalty Pharma, TPG, Orbimed, and MidCap Financial.
BioCryst operates through Biocryst Pharmaceuticals, Inc..